XML 51 R39.htm IDEA: XBRL DOCUMENT
v3.22.1

Collaboration and Licensing Agreements - Narrative (Details) ¥ in Billions | 1 Months Ended | 3 Months Ended | 53 Months Ended |  |
--- | --- | --- | --- | --- | ---
Nov. 30, 2019 USD ($) item | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Nov. 30, 2017 USD ($) | Jun. 30, 2015 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Mar. 31, 2022 USD ($) | Apr. 11, 2022 USD ($) payment_tranche | Mar. 31, 2022 JPY (¥)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 468,000 | $ 6,582,000 |  |  |
Cost of revenue |  |  |  |  |  | 85,000 | 1,000,000 |  |  |
Licensing revenue |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 4,000 | 5,002,000 |  |  |
Product supply revenue |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 14,000 | 126,000 |  |  |
AstraZeneca |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Aggregate cost of revenue recognized |  |  |  |  |  | 11,700,000 |  | $ 11,700,000 |  |
2019 KKC Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 0 | 1,500,000 |  |  |
2019 KKC Agreement | KKC |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront license fees | $ 10,000,000 |  |  |  |  |  |  |  |  |
First installment of upfront license fees | $ 5,000,000 |  |  |  |  |  |  |  |  |
Term of payment of license fee, first installment | 30 days |  |  |  |  |  |  |  |  |
Second installment of upfront license fees | $ 5,000,000 |  |  |  |  |  |  |  |  |
Term of agreement | 2 years |  |  |  |  |  |  |  |  |
2019 KKC Agreement | KKC | Minimum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Number of separate collaborative agreements | item | 1 |  |  |  |  |  |  |  |  |
2017 KKC Agreement | Licensing revenue |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 0 | 5,000,000 | 10,000,000 |  |
2017 KKC Agreement | Product supply revenue |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 14,000 | 100,000 |  |  |
2017 KKC Agreement | KKC |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront license fees |  |  |  | $ 30,000,000 |  |  |  |  |  |
Potential development milestones |  |  |  | $ 55,000,000 |  |  |  |  |  |
Potential commercialization milestones |  |  |  |  |  | 69,700,000 |  | 69,700,000 |  | ¥ 8.5
Fosun Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 0 | 0 |  |  |
Fosun Agreement | Fosun Pharma |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  | $ 12,000,000 |  |  |  |  |  |  |
Potential development and commercialization milestones |  |  |  |  |  | $ 110,000,000 |  |  |  |
Threshold percentage of net sales for tiered royalties |  |  |  |  |  | 20.00% |  |  |  |
Knight Agreement | Knight |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 2,300,000 |  |  |  |  |  |  |  |
Potential development and commercialization milestones |  |  |  |  |  | $ 17,800,000 |  |  |  |
AZ Termination Agreement | AstraZeneca |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of royalty revenue |  |  |  |  | 10.00% |  |  |  |  |
Percentage of non-royalty revenue |  |  |  |  | 20.00% |  |  |  |  |
Maximum potential payment per agreement |  |  |  |  | $ 75,000,000 |  |  |  |  |
Cost of revenue |  |  |  |  |  | 100,000 | $ 1,000,000 |  |  |
Aggregate amount paid |  |  |  |  |  | $ 11,600,000 |  | $ 11,600,000 |  |
Subsequent event | 2017 KKC Agreement | KKC |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Fee receivable for reduction in royalty rate |  |  |  |  |  |  |  |  | $ 40,000,000 |
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche |  |  |  |  |  |  |  |  | 2 |

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees, First Installment + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees, Second Installment + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate + References No definition available. + Details
Name: | ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches + References No definition available. + Details
Name: | ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Potential Commercialization Milestones + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of future development and commercialization milestone under collaborative arrangements. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Potential Development Milestones + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialDevelopmentMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cost of revenue, aggregate amount recognized. + References No definition available. + Details
Name: | ardx_CostOfRevenueAggregateAmountRecognized
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of separate collaborative agreements. + References No definition available. + Details
Name: | ardx_NumberOfSeparateCollaborativeAgreements
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments of uncharged license fees, aggregate amount paid. + References No definition available. + Details
Name: | ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents percentage of non-royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfNonRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of agreement. + References No definition available. + Details
Name: | ardx_TermOfAgreement
Namespace Prefix: | ardx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of payment of first installment fee. + References No definition available. + Details
Name: | ardx_TermOfPaymentOfLicenseFeeFirstInstallment
Namespace Prefix: | ardx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the threshold percentage of net sales for tiered royalties. + References No definition available. + Details
Name: | ardx_ThresholdPercentageOfSalesForTieredRoyalties
Namespace Prefix: | ardx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 + Details
Name: | us-gaap_CostOfRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_AstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |